Le Lézard
Classified in: Health
Subject: FDA

Jenkins Eye Care Offers First and Only FDA-approved Trifocal Lens: AcrySof IQ PanOptix Trifocal IOL


HONOLULU, Sept. 9, 2019 /PRNewswire/ -- Ophthalmological surgeons Tyrie Jenkins, M.D. and Jeffrey Peterson, M.D., Ph.D., of Jenkins Eye Care, now offer cataract patients a trifocal lens that provides a combination of near, intermediate and distance vision. This lens is also an option for people 50 years and older wanting to reduce or eliminate their need for contacts or glasses.  

Jeffrey R. Peterson, M.D., Ph.D.

Dr. Peterson implanted his first trifocal lens on Thursday, Sept. 5. He is among the earliest in Hawaii to do so.

The first to receive U.S. Food and Drug Administration approval of a trifocal lens for lens replacement during cataract surgery, the AcrySof® IQ PanOptix® Trifocal Intraocular Lens (IOL) significantly reduces the need for glasses after surgery. It is made by Alcon.

"Ophthalmologists across the nation have been anticipating FDA approval of the trifocal lens for patients," said Dr. Peterson. "This cutting-edge lens improves range of vision. We are pleased to be among the first to offer it in Hawaii."

"For those who don't have cataracts but want to reduce their dependence on eyeglasses and contact lenses, the trifocal lens benefits are revolutionary," Dr. Jenkins added.

About Cataracts
A cataract is clouding in the natural lens of the eye. As a cataract develops, the eye's lens gradually becomes hard and cloudy, allowing in less light, making it difficult to see. Cataracts generally result from aging, but radiation exposure, taking steroids, diabetes, and eye trauma can accelerate development. Cataracts are the most common age-related eye condition and leading cause of preventable blindness. Twenty million in the U.S., age 40 and older have cataracts. Cataracts are treated by removing the eye's cloudy natural lens and surgically replacing it with an intraocular lens. More than 98 percent of cataract surgeries are considered successful, and patients typically can return to regular routines within 24 hours.

About Presbyopia
Presbyopia is a common, age-related vision condition in which the eye gradually loses the ability to focus on close objects. Almost everyone will experience presbyopia to some degree as they age, with symptoms first appearing as people enter their 40s and worsening into their 60s. In the U.S., an estimated 112 million experience vision issues due to presbyopia ? a number that's expected to continue increasing. The condition is not a disease, so there is not a cure. However, there are safe and effective ways to correct presbyopia, including eyeglasses, contact lenses, or refractive surgery.

For more information, contact Jenkins Eye Care at (808) 591-9911 or online at www.jenkinseyecare.com.

Media Contact:
Barbra Pleadwell
[email protected] ? (808) 292-3031

Tyrie Jenkins, M.D.

SOURCE Jenkins Eye Care


These press releases may also interest you

at 07:35
Cybin Inc. (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced...

at 07:30
MedBright AI Investments Inc. (the "Company" or "MedBright") today announced that Dermatology Institute & Skin Care Center (DISCC) has signed a 3 year contract to use the MedMatrix AI Platform, including all 5 product modules in their single clinic...

at 07:30
UniDoc Health Corp. (FRA: L7T) ("UniDoc," or the "Company"), an innovator in the eHealth sector, proudly announces the deployment of an H3 Health Cube to Ketchikan, Alaska. This initiative, in collaboration with Planet Defense, LLC, marks a...

at 07:30
Virax Biolabs Group Limited ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it will be hosting a booth at the European Society of...

at 07:25
Cardiawave SA, a French Medtech company that has developed an innovative Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, is delighted to announce the appointment of Olivier Pierron as...

at 07:15
Arch Biopartners Inc., ("Arch" or the "Company") , announced today that a research team from St. Michael's Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac...



News published on and distributed by: